Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03992170 | Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive(DART4MM) | unknown | Phase 2 | 50 | Azienda Ospedaliera Universitaria SeneseOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03931421 | B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 4, 2019 |
| clinicaltrials |
| NCT03799224 | Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia | unknown | Phase 2 / Phase 3 | 55 | Peking University People's HospitalOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT02965092 | CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 80 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03366350 | Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 50 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03940833 | Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT03929107 | Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma. | unknown | Phase 2 | 80 | Wenbin QianOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT02747732 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | unknown | Phase 2 | 72 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03569696 | Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy(NivoM) | unknown | Phase 2 | 50 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03021057 | Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas | unknown | Phase 2 | 33 | The University of Hong KongOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02310243 | Study of Palbociclib in MLL-rearranged Acute Leukemias | unknown | Phase 1 / Phase 2 | 50 | University of UlmOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03902197 | CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients | unknown | Phase 2 | 50 | Xuanwu Hospital, BeijingOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03250962 | SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 280 | Chinese PLA General HospitalOTHER | 1 | Apr 1, 2019 | clinicaltrials |
| NCT03348033 | Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT02652910 | Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma(MeCAR) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT01670370 | Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 15, 2019 | clinicaltrials |
| NCT03258047 | Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma | unknown | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01240525 | Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers(ProT4) | unknown | Phase 2 | 114 | University College, LondonOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00863460 | Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients(PRECIS) | unknown | Phase 2 | 140 | Institut CurieOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02032446 | Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease(PTC-UC-MSC) | unknown | Phase 1 / Phase 2 | 47 | A.O. Ospedale Papa Giovanni XXIIIOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT03312205 | CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jan 9, 2019 | clinicaltrials |
| NCT03697655 | Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma(PREDATOR) | unknown | Phase 2 | 274 | Polish Myeloma ConsortiumOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03776279 | A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma | unknown | Phase 2 | 106 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03767751 | A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02537977 | CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy | unknown | Phase 1 / Phase 2 | 60 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT03746652 | Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma(DARIA) | unknown | Phase 2 | 50 | Hellenic Society of HematologyOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT03366324 | Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | unknown | Phase 1 / Phase 2 | 20 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | Nov 20, 2018 | clinicaltrials |
| NCT02542124 | NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | unknown | Phase 2 | 10 | Neumedicines Inc.INDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03454984 | SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation | unknown | Phase 2 | 40 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT03601624 | Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans(MM-POM-2018) | unknown | Phase 2 | 18 | Instituto de Seguridad y Servicios Sociales de los Trabajadores del EstadoOTHER_GOV | 1 | Nov 14, 2018 | clinicaltrials |
| NCT01332006 | Intra-bone Cord Blood Transplantation | unknown | Phase 2 | 17 | Università degli Studi di BresciaOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03679455 | A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1(OBI-1) | unknown | Phase 2 | 30 | Polish Myeloma ConsortiumOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03733327 | BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 20 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03733340 | Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT | unknown | Phase 2 / Phase 3 | 250 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03719989 | Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(EPIC) | unknown | Phase 2 | 27 | Seoul National University HospitalOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00439920 | GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL. | unknown | Phase 2 | — | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Oct 23, 2018 | clinicaltrials |
| NCT02717884 | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)(TRANSATRA) | unknown | Phase 1 / Phase 2 | 60 | Michael LuebbertOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT03665480 | The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03701022 | PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma | unknown | Phase 2 | 61 | Peking UniversityOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT03701217 | Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML | unknown | Phase 2 / Phase 3 | 220 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03642236 | Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT02572492 | Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support(CARFI) | unknown | Phase 2 | 200 | Henrik GregersenOTHER | 5 | Aug 17, 2018 | clinicaltrials |
| NCT02333838 | Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies(TBF-Cord) | unknown | Phase 2 | 31 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT03613428 | Ruxolitinib Plus LVP in Patients With R/R ETP-ALL | unknown | Phase 1 / Phase 2 | 12 | Sichuan UniversityOTHER | 0 | Aug 3, 2018 | clinicaltrials |
| NCT03201471 | Chidamide With R-CHOP Regimen for DLBCL Patients(DLBCL) | unknown | Phase 2 | 39 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT03605056 | Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM | unknown | Phase 2 | 25 | Peng LiuOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT03598959 | Tofacitinib Combined With Chidamide in R/R ENKTCL | unknown | Phase 2 | 20 | Sichuan UniversityOTHER | 1 | Jul 26, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jun 20, 2019source: clinicaltrials